AdamMBrufskyMD

PubMed

• Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.
  Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky
  Future Oncology. 2025-01-26
• Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
  Charles E Geyer Jr, Michael Untch, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas
  The New England Journal of Medicine. 2025-01-16
• Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits" and "Annual Versus Biennial Mammographic Screening".
  Margarita L Zuley, Andriy I Bandos, Stephen W Duffy, Durwin Logue, Rohit Bhargava
  Journal of Clinical Oncology. 2024-12-17

Journal Articles

• Molecular Mechanisms Linking High Body Mass Index to Breast Cancer Etiology in Post-Menopausal Breast Tumor and Tumor-Adjacent Tissues  
  Adam M Brufsky, Tari A King, Susan B Brown, Breast Cancer Research and Treatment
• Nab-Paclitaxel plus Carboplatin or Gemcitabine vs Gemcitabine plus Carboplatin as First-Line Treatment for Patients with Triple-Negative Metastatic Breast Cancer: Resu...  
  H Ali, A Brufsky, M Shtivelband, S Gluck, J Miller, R Young, Annals of Oncology
• Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer  
  Matthew P Goetz, Thomas J Saphner, Joseph A Sparano, Lynne I Wagner, Peter M Ravdin, Daniel F Hayes, Adam M Brufsky, Della F Makower, Sunil S Badve, Robert J Gray, Wil..., The New England Journal of Medicine

Lectures

• A Metastatic Breast Cancer Patient with Activating HER2 Exon 20 Insertion Mutation Responds to Poziotinib; A Case Report of Compassionate Drug Use 
  2019 ASCO Annual Meeting - 6/1/2019